In this study hot-melt co-extrusion is used as processing technique to manufacture a fixed-29 dose combination product providing enteric protection to naproxen incorporated in the core 30 and immediate release to esomeprazole magnesium embedded in the coat. The plasticizing 31 effect of naproxen and triethyl citrate (TEC) was tested on the enteric polymers investigated 32 (Eudragit ® L100-55, HPMC-AS-LF and HPMCP-HP-50). Core matrix formulations containing 33 HPMC-AS-LF, TEC and a naproxen load of 15, 30 and 50% were processed and 34 characterized. The in vitro naproxen release in 0.1N HCl was prevented for 2h for all 35 formulations. The physicochemical state of the drug in the extrudates was determined and a 36 stability study was performed. Intermolecular interactions between naproxen and polymer were 37 identified using attenuated total reflection Fourier-transform infrared (ATR FT-IR) 38 spectroscopy. When esomeprazole magnesium was formulated in a polyethylene oxide 39 100K:polyethylene glycol 4K (1:1) matrix, separated from the naproxen-containing layer, the 40 formulation could be easily processed and complete in vitro drug release was observed after 41 45min. When co-extruding the core/coat dosage form it was observed that a third layer of 42 polymer, separating the naproxen loaded enteric formulation in the core from the coat, is 43 required to prevent degradation of the acid-labile esomeprazole magnesium at the core/coat 44 interface. 45 46 47 48 49
INTRODUCTION
materials creating a multi-layered extrudate (Vynckier et al., 2014a) . This continuous 58 manufacturing technique still has to break through in pharmaceutical production, although 59 several literature reports are already available on the use of co-extrusion for oral drug delivery. 60
Quintavalle et al. (Quintavalle et al., 2007 (Quintavalle et al., , 2008 were the first to produce cylindrical co-61 extrudates with controlled drug release via hot-melt extrusion, using polyethylene glycol as 62 hydrophilic matrix and stearic acid or microcrystalline wax as hydrophobic matrix. Co-extruded 63 mini-matrices have recently been formulated using core/coat technology with drugs 64 incorporated in different polymer matrices in order to steer the release of different drugs 65 The present study investigated if hot-melt co-extrusion allowed to manufacture a fixed-70 dose combination product providing enteric protection to the active pharmaceutical ingredient 71
MATERIALS AND METHODS

85
Materials 86
Naproxen (pKa 4.15) (Fagron, Waregem, Belgium) and esomeprazole magnesium 87 trihydrate (Nifty labs, Hyderabad, India) were chosen as model drugs. Vimovo ® (AstraZeneca, 88 Brussels, Belgium), containing 500 mg enteric-coated naproxen and 20 mg non-enteric coated 89 esomeprazole Mg, was used as a commercially available reference. The following enteric 90 polymers were used: methacrylic acid -ethyl acrylate copolymer (1:1) Type A (Eudragit ® L100-91 55, Evonik, Darmstadt, Germany), hydroxypropyl methylcellulose acetate succinate (HPMC-92 AS-LF, Aqoat ® AS-LF, Shin-Etsu, Tokyo, Japan) and hydroxypropyl methylcellulose phthalate 93 (HPMCP-HP-50, Shin-Etsu, Tokyo, Japan). Triethyl citrate (TEC, Sigma-aldrich, Bornem, 94
Belgium) and talc (Luzenac ® Pharma, Imerys Talc, Gent, Belgium) were used as excipients in 95 the core formulation. The polymers used in the coat formulation were polyethylene oxide 100K 96 (PEO 100K, Mw: 100000 g/mol, SentryTM Polyox ® WSR N10, Colorcon, Dartford Kent, United 97 Kingdom), polyvinylpyrrolidone (Kollidon ® 12 PF, Mw: 2500 g/mol, BASF, Ludwigshafen, 98
Germany), hydroxypropyl methylcellulose (Methocel ® E3, viscosity: 3 mPa.s, Colorcon, 99
Dartford Kent, United Kingdom), hydroxypropyl cellulose (Klucel ® EF, Mw: 80000, Ashland, 100
Covington, USA) and polyethylene glycol 4K (PEG 4K, Mw: 4000 g/mol, Fagron, Waregem, 101 Belgium). All other chemicals were of analytical grade. 102
Methods 103
Hot-melt extrusion and co-extrusion 104
In a first step hot-melt extrusion was performed to select an appropriate polymer matrix for 105 core and coat separately, using a co-rotating Prism Eurolab 16 mm fully intermeshing twin-106 screw extruder (ThermoFisher Scientific, Karlsruhe, Germany) connected to a co-extrusion die 107 having a core and coat insert with a diameter of 4 and 6 mm, respectively (Guill, West Warwick, 108 USA). For the core formulations the processing temperatures are given in Table 1 . The coat 109
formulation was processed at a temperature of 100 °C in all zones of the extruder and the die. 110 g/h for the coat and 300 g/h for the core material. A screw speed of 120 rpm was used for each 113 of the extruders. 114
In a second phase co-extrusion was carried out using two co-rotating Prism Eurolab 16 115 mm twin-screw extruders (ThermoFisher Scientific, Karlsruhe, Germany), both connected to 116 the co-extrusion die (Guill, West Warwick, USA). A cylindrical co-extrudate with a core 117 diameter of 4 mm and a concentric coat with a thickness of 1 mm (total co-extrudate diameter: 118 6 mm) was manufactured. After cooling to room temperature the cylindrical co-extrudate was 119 manually cut into cylinders of 10 mm length, which were used for further analysis. 120
In vitro drug release 121
In vitro dissolution was performed using United States Pharmacopeia (USP) dissolution 122 apparatus 2 (paddles) on an Evolution 6300 dissolution system (Distek, New Brunswick, New 123 Jersey, USA), coupled with an Evolution 4300 automatic dissolution sampler (Distek, New 124
Brunswick, New Jersey, USA). The temperature of the dissolution medium was kept at 37 ± 125 and acetonitrile (B). The gradient used was: a linear ramp from 0 to 5 min going from 85 % A 140 + 15 % B to 50 % A + 50 % B, changing over to 5 % A + 95 % B at 5.1 min, maintained for 1.8 141 min and afterwards changing over to chromatographic start conditions 85 % A + 15 % B from 142 6.9 min to 7 min, followed by an equilibration of 3 min preceding the next injection. An Acquity 143 CSH C18 column (1.7 µm particle size, 2.1 x 100 mm) (Waters, Brussels, Belgium) was used 144 in an oven set at 40 °C. The flow rate was set at 0.35 ml/min, injection volume was 0.3 µl. A 145 photo-diode array detector (Acquity, Waters, Brussels, Belgium) was used. For the 146 quantification of esomeprazole a detection wavelength of 290 nm was used, whereas for 147 naproxen the detection wavelength was set at 260 nm. An appropriate calibration curve was 148 applied for quantification of esomeprazole and naproxen, respectively. 149
For the quantification and purity determination of esomeprazole in the solid dosage forms 150 a verified UHPLC method was developed, using an Acquity CSH C18 column (1.7 µm particle 151 size, 2.1 x 100 mm) (Waters, Brussels, Belgium) in an oven set at 40 °C, with a gradient system 152 min, maintaining this condition for 4.9 min as an equilibration step preceding a next injection. 157
The flow rate was set at 0.35 ml/min, an injection volume of 1.2 µl was used. For the 158 quantification of esomeprazole a photo-diode array detector (Acquity, Waters, Brussels, 159 Belgium), with a detection wavelength set at 301 nm, was used. Sample preparation was 160 performed by stirring the extrudates in a 10 ml flask filled with demineralized water : acetonitrile 161 in a 1 : 1 ratio. An appropriate calibration curve was applied for quantification of esomeprazole. 162
The UHPLC system consisted of an isocratic solvent pump, an automatic autosampler and compounds, physical mixtures and corresponding extrudates were studied using a differential 168 scanning calorimeter Q2000 V24.8 equipped with a refrigerated cooling system (TA 169
Instruments, Leatherhead, UK). Nitrogen was used as purge gas through the DSC cell (50 170 ml/min) and the RCS unit (300 ml/min). Samples (± 8 mg) were run in hermetically closed 171
Tzero pans with perforated lid, supplied by TA Instruments, with an underlying heating rate of 172 2 °C/min. The modulation period and amplitude were set at 60 s and 0.318 °C, respectively. cycle to ensure maximal interaction between the compounds and to simulate a thermal history 182 comparable to the extrudates when analyzed during the first heating cycle in MDSC. The 183 degree of crystallinity was calculated comparing the melting enthalpy of the naproxen melting 184 peak in the analyzed sample to that of pure naproxen (147.2 J/g). 185
X-ray diffraction 186
Crystallinity was analyzed using X-ray diffraction (XRD) on pure compounds, physical 187 mixtures and corresponding extrudates. X-ray diffraction was performed on a D5000 188 diffractometer with Cu Kα radiation (λ = 1.54 Å) (Siemens, Karlsruhe, Germany) and a voltage 189 of 40 mV in the angular range (2θ) varying from 4 to 60 ° using a step scan mode with a step 190 size of 0.02 ° and a measuring time of 1 s/step.
Attenuated total reflection Fourier-transform infrared (ATR FT-IR) spectroscopy was 193
performed on the pure substances, physical mixtures and extrudates to identify molecular 194 interactions formed between naproxen and the enteric polymers during extrusion. Spectra 195 were recorded in absorbance mode using a Nicolet iS5 ATR FT-IR spectrometer 196 (ThermoFisher Scientific, Karlsruhe, Germany). A diamond ATR crystal was pressed against 197 the samples in order to obtain the ATR FT-IR spectra in the 4000 -550 cm -1 range, with a 198 resolution of 4 cm -1 , averaged over 32 scans. 199
Stability study 200
Clear core extrudates formulated with different polymer matrices and 30 % naproxen 201 (Table 1) , and core extrudates containing 50 % naproxen and 50 % HPMC-AS-LF were 202 manufactured to perform a stability study. Immediately after extrusion, the formulations were 203 filled in an amber glass container and stored in closed condition at 25 °C / 60 %RH and in open 204 and closed condition at 40 °C / 75 %RH. To investigate the influence of storage MDSC, XRD, 205 and in vitro drug release tests were performed on the extrudates immediately after 206 manufacturing (T0), after 1 week (T1w), 2 weeks (T2w), 1 month (T1m) or 6 weeks (T6w), 3 207 months (T3m) and 6 months (T6m) storage.
RESULTS AND DISCUSSION
layers were first independently developed. Afterwards the compatibility of the core and coat 212 matrices was checked. Finally it was evaluated if the final drug-loaded formulations were 213 compatible and if a fixed-dose combination product with the desired release characteristics 214 could be manufactured via co-extrusion. 215
Core formulation 216
To develop a core matrix formulation providing enteric protection for naproxen, using hot-217 melt extrusion (HME) as production technology, three enteric polymers were compared: 218 methacrylic acid -ethylacrylate copolymer (Eudragit ® L100-55), hypromellose acetate 219 succinate (HPMC-AS-LF) and hypromellose phthalate (HPMCP-HP-50). Hot-melt extrusion of 220 these polymers in combination with 15% naproxen required a plasticizer as without plasticizer 221
the torque values during extrusion were too high. Although naproxen (with a melting point at 222 156.1 °C and a glass transition temperature (Tg) of 6.2 °C) (Alleso et al., 2009) had a 223 concentration-dependent plasticizing effect on these polymers (Table 2) , the effect of this 224 polymer/drug interaction on the process temperature and/or torque during extrusion cannot be 225 exploited to its full extent as the plasticizing effect was only evident during the second heating 226 cycle of the MDSC analysis of a physical mixture. Hence, these drug/polymer interactions were 227 only established after intense intermolecular contact following the 1 st heating phase of the 228 MDSC experiment. 229 TEC was an efficient plasticizer for Eudragit ® L100-55, reducing its Tg from 117.7 °C to 230 108.5 and 90.2 °C after the 1 st and 2 nd heating cycle, respectively, at a concentration of 10 % 231 TEC. For this formulation a screw speed of 120 rpm and a higher processing temperature at 232 the die-end of the barrel was required to reduce die swell. The addition of 10 % talc to the 233 formulation was critical as it improved the flow properties of the powder, ensuring consistent 234 feeding of the powder into the extruder. When 10 % TEC was added to HPMC-AS-LF the Tg 235 lowered from 122.8 °C to 97.5 and 91.1 °C after the 1 st and 2 nd heating cycle respectively. This formulation, containing 15 % naproxen, yielded an extrudate with a smooth appearance and enteric polymer reduced Tg from 142.1 °C to 126.6 and 95.7 °C after the 1 st and 2 nd heating 239 cycle, respectively. The 15 % drug-loaded formulation yielded extrudates that were 240 processable at 145 °C, but had an irregular surface. 241
At a 15 % naproxen content hot-melt extrusion of all polymer formulations resulted in clear 242 extrudates with the entire drug content molecularly dispersed in the polymer matrix. A higher 243 drug load (30 %) resulted in opaque formulations with a significant degree of crystallinity. 244
However, the extrusion temperature was critical to the physicochemical state of the drug in the 245 extrudates as nearly the entire naproxen content was molecularly dispersed in the polymer 246 matrices when processed at a higher temperature (Table 1) respectively. This was also reflected in the X-ray diffractogram of the Eudragit ® L100-55 249 extrudates processed at different extrusion temperatures (Fig. 1) . Interestingly the 250 hypromellose-based polymers containing a higher naproxen content could be extruded at a 251 lower temperature, even when they contained a significant crystalline drug fraction. This can 252 be linked to the plasticizing effect of naproxen on these polymers: thermal processing of 253 mixtures with a higher drug content induced more interaction between drug and polymer in the 254 extrusion barrel. Hence, a lower extrusion temperature could be employed, without risking too 255
high torque values. This plasticizing effect of naproxen was even more evident for a HPMC-256
AS-LF formulation containing 50 % naproxen which could be processed without plasticizer at 257 an extrusion temperature of 120/120/120/110/110/100/100 °C from feed opening to die-end, 258 despite its high percentage of crystalline drug. 259
The in-vitro naproxen release profiles of the different polymer formulations containing 10 260 % TEC as a plasticizer and loaded with 15 % naproxen are shown in Fig. 2 . For all formulations 261 naproxen release in 0.1 N HCl was prevented for 2 h. In pH 6.8 buffer HPMCP-HP-50 matrices 262 showed a faster release rate compared to HPMC-AS-LF and Eudragit ® L100-55 formulations. naproxen formulations, it did not have a significant effect on the release profiles. The enteric 265 protection of naproxen during a 2 h period was not impaired in formulations containing 30 and 266 50 % drug. However, naproxen release in pH 6.8 buffer was determined by drug concentration: 267 after 2 h HPMC-AS-LF matrices containing 30 and 50 % naproxen released 58 and 81 % of 268 their drug content, respectively (Fig. 3) . Drug release form the core matrix was diffusion and 269 erosion controlled as it was observed that the core slowly eroded during dissolution testing. shown in Fig. 4 and Fig. 5 it is suggested that naproxen is mainly molecularly dispersed in the 282 formulation immediately after processing, since some of the peaks characteristic for naproxen 283 completely disappeared, e.g. peaks at 1347 cm -1 (rocking of OH of the carboxyl group (Balci, 284 2014)) and 642 cm -1 (wagging of OH of the carboxyl group (Balci, 2014)), while others 285 broadened, e.g. peaks at 1416 cm -1 (in-plane bending of CH of the naphthalene ring (Balci, 286 2014)) and 1628 cm -1 (bond stretching of the naphthalene ring (Balci, 2014)), confirming the 287 loss of crystalline material (1.3 %). After storage for 2 weeks at 40 °C / 75 %RH the visual 288 recrystallization in the extrudate was confirmed by the appearance of characteristic naproxen 289 peaks in the FT-IR spectra (Fig. 5) . The changing ratio between the peaks at 1727 cm -1 and 290 1686 cm -1 (attributed to non-hydrogen and hydrogen bonded -C=O stretching of the crystal 291 structure (Paudel and Van den Mooter, 2012)) before and after storage implied that the amount 292 time (Fig. 6 ). While the interaction between drug and polymer is maximal immediately after 294 processing, the reduction of the peak at 1686 cm -1 after storage clearly indicated that the 295 amount of hydrogen bonds decreased. The peak shifts observed in the extrudates for the 296 naproxen peaks at 1227 cm -1 (stretching of CO of the methoxy group (Balci, 2014)) and 1603 297 cm -1 (bond stretching of the naphthalene ring (Balci, 2014)) are another indication of the 298 hydrogen bond interaction between drug and matrix (Fig. 4) . Also the HPMC-AS-LF 299 formulations showed a partial recrystallization over time. The characteristic naproxen peaks 300 were more pronounced in the FT-IR spectra of the extrudates after storage. Moreover after 301 storage the characteristic naproxen peaks in the FT-IR spectra of the extrudate were not 302 different from those of pure naproxen (Fig. 7) . Also at 1727 and 1686 cm -1 (Fig. 8 ) the FT-IR 303 spectrum of the stored extrudate has the same profile as pure drug. This indicated that there 304 is no permanent interaction between HPMC-AS-LF and naproxen. 305
Coat formulation 306
Formulation of esomeprazole magnesium presents a challenge since degradation of the 307 drug can occur due to a high process temperature and in acidic environment (Razzaq et al., 308 2012) . When formulating esomeprazole magnesium in the enteric polymers Eudragit ® L100-309 55, HPMC-AS-LF and HPMCP-HP-50 complete degradation of the drug occurred, most likely 310 due to the presence of acidic groups in the polymers. Therefore esomeprazole magnesium 311 was formulated in an immediate release polymer, separated from the naproxen-containing 312 enteric layer. A similar approach was used in a commercially available combination product of 313 naproxen and esomeprazole magnesium (Vimovo ® ) which is formulated as an enteric-coated 314 naproxen tablet with a non-enteric-coated esomeprazole magnesium layer on top (both layers 315 are physically separated via a barrier coat). The immediate release polymers tested were PEO 316 100K, Kollidon ® 12 PF, Klucel ® EF and Methocel ® E3. While extrusion of the PEO 100K 317 formulation was feasible at a process temperature of 100 °C, the other polymers required a 318 processing temperature of 130 °C, even with the addition of a plasticizer, and as a result more 319 release from the PEO 100K polymer was limited to 70 % after 45 min, PEG 4K was added to 322 the mixtures: complete drug release was observed after 45 min in combination with smooth 323 processing (lower torque) for a 2 % esomeprazole magnesium loaded PEO 100K : PEG 4K (1 324 : 1) formulation (Fig. 9) . The coat layer rapidly and completely dissolved during dissolution 325
testing. 326
Thermal analysis of the physical mixture and the extruded formulation only revealed a 327 melting endotherm of PEO 100K and PEG 4K, due to dissolution of the esomeprazole 328 magnesium crystals in molten polymer. While two distinct melting endotherms were detected 329 for the physical mixture, only a single endotherm was visible in the extruded sample, indicating 330 the formation of a single phase system. 331
Co-extrudate formulation 332
After evaluating the naproxen-containing enteric layer and the esomeprazole magnesium-333 containing immediate release layer separately, co-extrusion of 50 % naproxen in the HPMC-334 AS-LF core and 2 % esomeprazole magnesium in the PEO 100K : PEG 4K 1:1 coat yielded 335 an opaque co-extrudate with a smooth surface. However, after cooling of the co-extrudate 336 discoloration was observed at the interface of core and coat (Fig. 10) , and in vitro dissolution 337 revealed that only 72 % of the esomeprazole content could be recovered, despite the fast and 338 complete dissolution of the PEO / PEG layer. Since this was not seen when processing the co-339 extrudate with a placebo HPMC-AS-LF + 10 % TEC core, the discoloration is most probably 340 due to an interaction between the naproxen fraction at the core surface and esomeprazole 341 magnesium in the coat, leading to degradation of the acid-labile esomeprazole magnesium. A 342 possible solution to this problem could be the extrusion of a barrier layer between core and 343 coat. This technique is already applied for the production of multi-layer films in packaging 344 applications (Thellen et al., 2009 (Thellen et al., , 2012 ), but could not be evaluated at this stage as it implies 345 the use of a third extruder. Dissolution in demineralized water for 2 h at 37 °C using paddle dissolution system at 100 rpm 469 (Mean ± SD; n=3). 470 Eudragit ® L100-55 plasticized with 10 % TEC and a drug load of 30 % naproxen (red) and the 499 extrudate of the same formulation immediately after processing (yellow). 500 501 502 plasticized with 10 % TEC and a drug load of 30 % naproxen (red) and the extrudate of the 504 same formulation immediately after processing (yellow) and after storage for 2 weeks at 40 °C 505 / 75 %RH (grey). 506 formulation immediately after processing (yellow) and after storage for 2 weeks at 40 °C / 75 511 %RH (grey). 512 Fig. 7 . ATR FT-IR spectra of naproxen (blue), HPMC-AS-LF (green), the physical mixture of 515 HPMC-AS-LF plasticized with 10 % TEC and a drug load of 30% naproxen (red), the extrudate 516 of the same formulation immediately after processing (yellow) and after storage for 2 weeks at 517 40 °C / 75 %RH (grey). 
